Bioxytran, Inc. (OTCMKTS:BIXT) Sees Significant Growth in Short Interest

Bioxytran, Inc. (OTCMKTS:BIXT) saw a significant increase in short interest in May. As of May 15th, there was short interest totaling 14,198 shares, an increase of 4,632.7% from the April 30th total of 300 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average trading volume of 81,682 shares, the short-interest ratio is currently 0.2 days.

Bioxytran Trading Up 6.0%

BIXT opened at $0.03 on Friday. The firm has a market cap of $3.63 million, a P/E ratio of -1.59 and a beta of 1.95. Bioxytran has a 12 month low of $0.03 and a 12 month high of $0.16. The stock has a 50-day moving average of $0.04 and a 200 day moving average of $0.05.

Bioxytran (OTCMKTS:BIXT) last released its quarterly earnings results on Friday, May 15th. The company reported ($0.02) EPS for the quarter.

Bioxytran Company Profile

Bioxytran, Inc is a clinical-stage biotechnology company focused on the development of synthetic oxygen carriers and novel oxygen therapeutics for acute care and chronic disease applications. The company’s proprietary platform is designed to safely deliver therapeutic levels of oxygen to hypoxic tissues, addressing conditions such as ischemia-reperfusion injury, organ transplantation, and traumatic injury. Its lead product candidates target unmet medical needs in cardiovascular and neurological disorders, wound healing, and critical care settings.

Bioxytran’s research pipeline comprises multiple preclinical-stage assets that leverage stabilized perfluorocarbon emulsions to achieve controlled oxygen release.